Valproate (VPA) is broad-spectrum antiepileptic drug. Several adverse reactions including hepatotoxicity, fetal risk and pancreatitis are well known and labelled as boxed warnings in the USA. One adverse reaction that is less well known but clinically significant for its severe morbidity is hyperammonemic encephalopathy. We present a case of woman with hyperammonemic encephalopathy following the initiation of VPA therapy; she had a favourable outcome with discontinuation of the drug and prompt treatment with lactulose and L-carnitine.
Keywords: Drugs: CNS (not psychiatric); Healthcare improvement and patient safety; Psychiatry (drugs and medicines); Safety; Unwanted effects / adverse reactions.
© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.